ACOU085 (Bimokalner)

About Acousia Therapeutics

Acousia Therapeutics is a clinical-stage biotech pioneer focused on creating the first pharmacological treatments for sensorineural hearing loss (SNHL), a condition affecting over 90% of hearing loss patients. Its most advanced program, ACOU085, is in a Phase 2 study for preventing cisplatin-induced hearing loss, with a parallel development path for age-related hearing loss. The company's drug candidates feature a unique dual mode of action aimed at both protecting and enhancing hearing, potentially as stand-alone or complementary therapies to devices like hearing aids. Backed by a strong academic collaboration, Acousia is positioned in a large, underserved market with no currently approved drugs.

About Acousia Therapeutics

Acousia Therapeutics is a clinical-stage biotech pioneer focused on creating the first pharmacological treatments for sensorineural hearing loss (SNHL), a condition affecting over 90% of hearing loss patients. Its most advanced program, ACOU085, is in a Phase 2 study for preventing cisplatin-induced hearing loss, with a parallel development path for age-related hearing loss. The company's drug candidates feature a unique dual mode of action aimed at both protecting and enhancing hearing, potentially as stand-alone or complementary therapies to devices like hearing aids. Backed by a strong academic collaboration, Acousia is positioned in a large, underserved market with no currently approved drugs.

About Acousia Therapeutics

Acousia Therapeutics is a clinical-stage biotech pioneer focused on creating the first pharmacological treatments for sensorineural hearing loss (SNHL), a condition affecting over 90% of hearing loss patients. Its most advanced program, ACOU085, is in a Phase 2 study for preventing cisplatin-induced hearing loss, with a parallel development path for age-related hearing loss. The company's drug candidates feature a unique dual mode of action aimed at both protecting and enhancing hearing, potentially as stand-alone or complementary therapies to devices like hearing aids. Backed by a strong academic collaboration, Acousia is positioned in a large, underserved market with no currently approved drugs.

About Acousia Therapeutics

Acousia Therapeutics is a clinical-stage biotech pioneer focused on creating the first pharmacological treatments for sensorineural hearing loss (SNHL), a condition affecting over 90% of hearing loss patients. Its most advanced program, ACOU085, is in a Phase 2 study for preventing cisplatin-induced hearing loss, with a parallel development path for age-related hearing loss. The company's drug candidates feature a unique dual mode of action aimed at both protecting and enhancing hearing, potentially as stand-alone or complementary therapies to devices like hearing aids. Backed by a strong academic collaboration, Acousia is positioned in a large, underserved market with no currently approved drugs.

About Acousia Therapeutics

Acousia Therapeutics is a clinical-stage biotech pioneer focused on creating the first pharmacological treatments for sensorineural hearing loss (SNHL), a condition affecting over 90% of hearing loss patients. Its most advanced program, ACOU085, is in a Phase 2 study for preventing cisplatin-induced hearing loss, with a parallel development path for age-related hearing loss. The company's drug candidates feature a unique dual mode of action aimed at both protecting and enhancing hearing, potentially as stand-alone or complementary therapies to devices like hearing aids. Backed by a strong academic collaboration, Acousia is positioned in a large, underserved market with no currently approved drugs.

Therapeutic Areas